Literature DB >> 1330563

Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.

M S Barrett1, R N Jones.   

Abstract

Haemophilus influenzae strains with varied ampicillin resistance and beta-lactamase production patterns were tested against three investigational fluorinated quinolones (CI-960, fleroxacin, temafloxacin) using Haemophilus Test Medium (HTM) and National Committee for Clinical Laboratory Standards (NCCLS) methods. The disk diffusion zones and MICs were compared and regression statistics and scattergrams generated. The rank order of the agents according to activity against Haemophilus influenzae was CI-960 (MIC50 0.002 microgram/ml) greater than temafloxacin (MIC50 0.015 microgram/ml) greater than fleroxacin (MIC50 0.03 microgram/ml). The recommended susceptibility interpretive criteria for the 5-micrograms disks of each drug were: for CI-960 greater than or equal to 23 mm (MIC correlate less than or equal to 1 microgram/ml); for fleroxacin greater than or equal to 19 mm (MIC correlate less than or equal to 2 micrograms/ml); and for temafloxacin greater than or equal to 16 mm (MIC correlate less than or equal to 2 micrograms/ml). All recent Haemophilus influenzae isolates tested were susceptible to these potent fluoroquinolones and no interpretive errors were observed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330563     DOI: 10.1007/bf01961865

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.

Authors:  R N Jones; M E Erwin; M S Barrett
Journal:  Diagn Microbiol Infect Dis       Date:  1992 May-Jun       Impact factor: 2.803

3.  Problems with current recommendations for susceptibility testing of Haemophilus influenzae.

Authors:  P M Mendelman; E A Wiley; T L Stull; C Clausen; D O Chaffin; O Onay
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.

Authors:  P C Fuchs; R N Jones; A L Barry; L W Ayers; T L Gavan; E H Gerlach; C Thornsberry
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

5.  Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

6.  In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; C L Heifetz
Journal:  Diagn Microbiol Infect Dis       Date:  1991 May-Jun       Impact factor: 2.803

7.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

8.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

9.  MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  2 in total

1.  Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Quality Control Study Group.

Authors:  M J Bale; R N Jones
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

Review 2.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.